Dupixent (dupilumab) is FDA approved for individuals aged six months and older for certain inflammatory conditions [1]. The specific age approval can vary depending on the indication for which the drug is being used [2].
How young can a child be to use Dupixent?
The U.S. Food and Drug Administration (FDA) has approved Dupixent for use in children as young as six months old for the treatment of moderate-to-severe atopic dermatitis [3]. For other approved conditions, the minimum age may differ.
What conditions is Dupixent approved for?
Dupixent is approved for a range of inflammatory conditions, including moderate-to-severe atopic dermatitis in adults and children six months and older [1, 3]. It is also indicated for moderate-to-severe eosinophilic esophagitis in individuals aged one year and older, and for moderate-to-severe asthma in patients aged four years and older [2, 4]. Additionally, Dupixent has approvals for chronic rhinosinusitis with nasal polyposy (CRSwNP) in adults and adolescents 12 years and older, and for prurigo nodularis in adults [5].
When does Dupixent's patent expire?
Patent exclusivity for Dupixent is a complex area, with multiple patents covering the drug and its uses [6]. According to DrugPatentWatch.com, the expected expiry dates for key patents are in the mid-2030s [6]. However, patent challenges and litigation can influence these timelines [6].
Are there any biosimilars for Dupixent?
As of now, there are no FDA-approved biosimilars for Dupixent [7]. Biosimilar development and approval processes typically follow the patent expiry of the reference biologic, though early patent challenges can sometimes affect timelines [6, 7].
Sources:
[1] https://www.dupixent.com/
[2] https://www.fda.gov/
[3] https://www.dupixent.com/dupixent-for-atopic-dermatitis
[4] https://www.dupixent.com/dupixent-for-asthma
[5] https://www.dupixent.com/dupixent-for-other-conditions
[6] https://www.drugpatentwatch.com/drug/dupilumab
[7] https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-reference-list